Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...

MBX Biosciences: Testing 2026 May Deliver Another Year Of Share Price Gains

MBX Biosciences, Inc. is rated a Buy, driven by canvuparatide's once-weekly dosing advantage in hypoparathyroidism. Learn ...
The Malaysian Reserve

Ascletis’ Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in ...

ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no ...

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

UCB, a global biopharmaceutical company, today presented positive efficacy and safety results from the GEMZ phase 3 study ...
Medindia

Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity

After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder

UCB, a global biopharmaceutical company, today presented positive efficacy and safety results from the GEMZ phase 3 study investigating adjunctive fenfluramine (FFA) in children and adults with CDKL5 ...

(PR) UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

The MarketWatch News Department was not involved in the creation of this content.-- Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a stati ...
Pharmabiz

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces CMSF in CDKL5 deficiency disorder

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces CMSF in CDKL5 deficiency disorder: Brussels, Belgium Tuesday, December 9, 2 ...

Innovent Biologics: Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity

After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body ...

Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript

Syndax Pharmaceuticals, Inc. ( SNDX) The 67th American Society of Hematology ( ASH) Annual Meeting December 8, 2025 7:00 AM EST ...

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in co ...
NPR

On Point with Meghna Chakrabarti

Get ready for your aha moment: Every weekday, host Meghna Chakrabarti pierces your news bubble to expose the whole story. Getting answers to the questions that need to be asked, examining our history ...